BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 35773148)

  • 1. Immune organoids: from tumor modeling to precision oncology.
    Dao V; Yuki K; Lo YH; Nakano M; Kuo CJ
    Trends Cancer; 2022 Oct; 8(10):870-880. PubMed ID: 35773148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
    Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
    Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.
    Jeong SR; Kang M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoid Models for Precision Cancer Immunotherapy.
    Sun CP; Lan HR; Fang XL; Yang XY; Jin KT
    Front Immunol; 2022; 13():770465. PubMed ID: 35450073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
    Xu H; Jiao D; Liu A; Wu K
    J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoid Models of Tumor Immunology.
    Yuki K; Cheng N; Nakano M; Kuo CJ
    Trends Immunol; 2020 Aug; 41(8):652-664. PubMed ID: 32654925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
    Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
    Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
    Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
    Pyo DH; Hong HK; Lee WY; Cho YB
    Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Organoids for Precision Cancer Immunotherapy.
    Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V
    Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
    Li J; Liu J; Xia W; Yang H; Sha W; Chen H
    Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived organoids as a model for tumor research.
    Wang J; Feng X; Li Z; Chen Y; Huang W
    Prog Mol Biol Transl Sci; 2022; 189(1):259-326. PubMed ID: 35595351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Cancer Medicine: An Organoid Approach.
    Aboulkheyr Es H; Montazeri L; Aref AR; Vosough M; Baharvand H
    Trends Biotechnol; 2018 Apr; 36(4):358-371. PubMed ID: 29366522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends.
    Song SL; Li B; Carvalho MR; Wang HJ; Mao DL; Wei JT; Chen W; Weng ZH; Chen YC; Deng CX; Reis RL; Oliveira JM; He YL; Yan LP; Zhang CH
    Pharmacol Ther; 2022 Nov; 239():108276. PubMed ID: 36055421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling.
    Hong HK; Yun NH; Jeong YL; Park J; Doh J; Lee WY; Cho YB
    Cancer Med; 2021 Aug; 10(16):5589-5598. PubMed ID: 34240815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor organoid models in precision medicine and investigating cancer-stromal interactions.
    Xu R; Zhou X; Wang S; Trinkle C
    Pharmacol Ther; 2021 Feb; 218():107668. PubMed ID: 32853629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer organoid co-culture model system: Novel approach to guide precision medicine.
    Yuan J; Li X; Yu S
    Front Immunol; 2022; 13():1061388. PubMed ID: 36713421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
    Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
    BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.